Fluidigm (FLDM) Reaches New 12-Month High at $8.69

Fluidigm Co. (NASDAQ:FLDM)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $8.69 and last traded at $8.48, with a volume of 27390 shares. The stock had previously closed at $8.25.

Several equities analysts recently commented on FLDM shares. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research raised Fluidigm from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Finally, Piper Jaffray Companies raised Fluidigm from a “neutral” rating to an “overweight” rating in a research report on Friday, November 2nd.

The stock has a market capitalization of $326.38 million, a P/E ratio of -6.96 and a beta of 2.84. The company has a quick ratio of 1.45, a current ratio of 1.85 and a debt-to-equity ratio of 7.56.

Fluidigm (NASDAQ:FLDM) last released its quarterly earnings results on Thursday, November 1st. The medical research company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.20). The company had revenue of $28.96 million for the quarter, compared to analyst estimates of $27.50 million. Fluidigm had a negative return on equity of 86.00% and a negative net margin of 50.46%. As a group, research analysts anticipate that Fluidigm Co. will post -0.99 EPS for the current year.

In other Fluidigm news, insider Levin Capital Strategies, L.P. bought 47,768 shares of the business’s stock in a transaction on Wednesday, November 14th. The shares were bought at an average cost of $7.55 per share, with a total value of $360,648.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 122,180 shares of company stock worth $910,163 over the last three months. 2.20% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in FLDM. Levin Capital Strategies L.P. raised its position in shares of Fluidigm by 5.1% in the 2nd quarter. Levin Capital Strategies L.P. now owns 10,208,322 shares of the medical research company’s stock valued at $60,842,000 after purchasing an additional 492,914 shares in the last quarter. Millennium Management LLC raised its position in shares of Fluidigm by 2,126.0% in the 1st quarter. Millennium Management LLC now owns 391,249 shares of the medical research company’s stock valued at $2,285,000 after purchasing an additional 373,673 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Fluidigm by 41.4% in the 2nd quarter. Acadian Asset Management LLC now owns 426,091 shares of the medical research company’s stock valued at $2,540,000 after purchasing an additional 124,708 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Fluidigm by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,070,500 shares of the medical research company’s stock valued at $6,380,000 after purchasing an additional 118,200 shares in the last quarter. Finally, Primecap Management Co. CA raised its position in shares of Fluidigm by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 5,856,043 shares of the medical research company’s stock valued at $43,862,000 after purchasing an additional 64,000 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Fluidigm (FLDM) Reaches New 12-Month High at $8.69” was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.wkrb13.com/2018/11/23/fluidigm-fldm-reaches-new-12-month-high-at-8-69.html.

About Fluidigm (NASDAQ:FLDM)

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Further Reading: Balanced Fund

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply